Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) reported Income from Continuing Operations of 205991000.0 for Q1 2026, up 1228.66% on a YoY basis from 15503712.44 in Q1 2025, and up 84.67% quarter-over-quarter from 111543000.0 in Q4 2025.
Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals has reported Income from Continuing Operations for 18 years, with the latest figure at 205991000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 1228.66% year-over-year to 205991000.0; the trailing twelve-month figure through Mar 2026 stood at 543940000.0 (up 336.01% YoY), and the FY2025 full-year result was 313747000.0, up 212.79% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 205991000.0, up from 111543000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 292683000.0 in Q3 2025, with the low at 405920000.0 in Q3 2022.
- Historically, Income from Continuing Operations has averaged 77874470.59 across 5 years, with a median of 83763000.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations tumbled 292.43% — and 2026, when it soared 1228.66%.
- Alnylam Pharmaceuticals' Income from Continuing Operations stood at 207493000.0 in 2022, then soared by 33.55% to 137870000.0 in 2023, then soared by 39.24% to 83763000.0 in 2024, then jumped by 233.17% to 111543000.0 in 2025, then jumped by 84.67% to 205991000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 205991000.0 (Q1 2026), 111543000.0 (Q4 2025), and 292683000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 205.99 Mn |
| Dec 31, 2025 | 111.54 Mn |
| Sep 30, 2025 | 292.68 Mn |
| Jun 30, 2025 | -66.28 Mn |
| Mar 31, 2025 | -18.25 Mn |
| Dec 31, 2024 | -83.76 Mn |
| Sep 30, 2024 | -111.57 Mn |
| Jun 30, 2024 | -16.89 Mn |
| Mar 31, 2024 | -65.94 Mn |
| Dec 31, 2023 | -137.87 Mn |
| Sep 30, 2023 | 147.75 Mn |
| Jun 30, 2023 | -276.02 Mn |
| Mar 31, 2023 | -174.10 Mn |
| Dec 31, 2022 | -207.49 Mn |
| Sep 30, 2022 | -405.92 Mn |
| Jun 30, 2022 | -277.40 Mn |
| Mar 31, 2022 | -240.34 Mn |
| Dec 31, 2021 | -258.46 Mn |
| Sep 30, 2021 | -204.51 Mn |
| Jun 30, 2021 | -189.56 Mn |